MX2021010115A - Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. - Google Patents

Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.

Info

Publication number
MX2021010115A
MX2021010115A MX2021010115A MX2021010115A MX2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A MX 2021010115 A MX2021010115 A MX 2021010115A
Authority
MX
Mexico
Prior art keywords
treatment
myeloid leukemia
acute myeloid
pharmaceutical composition
agent
Prior art date
Application number
MX2021010115A
Other languages
English (en)
Spanish (es)
Inventor
In Hwan Bae
Young Gil Ahn
Ji Sook Kim
Jae Yul Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Priority claimed from KR1020200021502A external-priority patent/KR20200102949A/ko
Publication of MX2021010115A publication Critical patent/MX2021010115A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021010115A 2019-02-22 2020-02-21 Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda. MX2021010115A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190021228 2019-02-22
KR1020200021502A KR20200102949A (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
PCT/KR2020/002536 WO2020171646A1 (ko) 2019-02-22 2020-02-21 Flt3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2021010115A true MX2021010115A (es) 2021-09-21

Family

ID=72144358

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010115A MX2021010115A (es) 2019-02-22 2020-02-21 Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda.

Country Status (8)

Country Link
US (1) US12433867B2 (cg-RX-API-DMAC7.html)
JP (1) JP7577672B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016522A2 (cg-RX-API-DMAC7.html)
CL (1) CL2021002217A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021010115A (cg-RX-API-DMAC7.html)
PE (1) PE20212153A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551985A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020171646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
EP3991733A4 (en) * 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20230056331A (ko) * 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
EP4525873A1 (en) 2022-05-17 2025-03-26 Biomea Fusion, Inc. Flt3 combination therapy for cancer and compositions therefor

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) 2005-01-11 2005-02-16 Cyclacel Ltd Compound
US20060281768A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Thienopyrimidine and thienopyridine kinase modulators
KR20090087094A (ko) 2006-11-28 2009-08-14 노파르티스 아게 Iap 억제제 및 flt3 억제제의 조합물
JPWO2008111441A1 (ja) 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
CA2702126A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide t-type calcium channel antagonists
FR2926553B1 (fr) 2008-01-23 2010-02-19 Sanofi Aventis Derives d'indole-2-carboxamides et d'azaindole-2- carboxamides substitues par un groupe silanyle, leur preparation et leur application en therapeutique
WO2010042337A1 (en) 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
TW201022262A (en) 2008-10-29 2010-06-16 Astrazeneca Ab Novel compounds 515
CN102438588B (zh) 2009-03-23 2015-04-01 埃姆比特生物科学公司 使用联合治疗法治疗疾病的方法
US8435980B2 (en) 2009-07-15 2013-05-07 Abbvie Inc. Pyrrolopyridine inhibitors of kinases
ES2622138T3 (es) 2010-06-23 2017-07-05 Hanmi Science Co., Ltd. Nuevos derivados de pirimidina condensados para la inhibición de la actividad tirosina quinasa
UY33539A (es) 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
DK3686193T3 (da) 2011-07-27 2022-05-30 Astrazeneca Ab 2-(2,4,5-substitueret anilino)pyrimidinforbindelser
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical HETEROCYCLIC COMPOUND
WO2014155300A2 (en) 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
MX358346B (es) 2014-04-04 2018-08-15 Syros Pharmaceuticals Inc Inhibidores de la quinasa dependiente de ciclina 7 (cdk7).
CA2949793C (en) 2014-06-19 2024-02-27 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN113121575A (zh) 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
JP6564449B2 (ja) 2015-02-20 2019-08-21 第一三共株式会社 がんの併用治療法
WO2016155655A1 (zh) 2015-04-03 2016-10-06 上海瑛派药业有限公司 Parp抑制剂固体药物剂型及其应用
KR101799781B1 (ko) 2015-07-23 2017-11-22 재단법인 강릉과학산업진흥원 소뼈 추출분말의 제조방법
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN107531725B (zh) 2015-08-13 2021-03-19 北京韩美药品有限公司 Irak4抑制剂及其应用
CA2998042C (en) 2015-09-14 2022-07-05 Brunangelo Falini Dactinomycin compositions and methods for the treatment of acute myeloid leukemia
BR112018009463A8 (pt) 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
SG10201913290QA (en) 2016-03-15 2020-03-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for the treatment of hematological malignancies
EP3436014A4 (en) * 2016-03-29 2019-11-27 Astellas Pharma Inc. COMBINATION THERAPY FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
EP3478675B1 (en) 2016-06-30 2020-04-22 Janssen Pharmaceutica NV Heteroaromatic derivatives as nik inhibitors
PL3541387T3 (pl) 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53
MA47233A (fr) 2016-12-19 2019-10-23 Epizyme Inc Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation
PE20191108A1 (es) 2017-01-17 2019-08-26 Astrazeneca Ab Inhibidores selectivos de jak1
KR102175710B1 (ko) 2017-01-23 2020-11-06 주식회사 엘지화학 폴리아릴렌 설파이드 수지 조성물
TWI810172B (zh) 2017-01-26 2023-08-01 南韓商韓美藥品股份有限公司 嘧啶化合物及包括其的藥學組成物
KR20190128646A (ko) 2017-02-21 2019-11-18 압토스 바이오사이언시스 인코포레이티드 혈액 종양 환자들의 치료 방법
WO2019025484A1 (en) 2017-08-01 2019-02-07 Julius-Maximilians-Universität Würzburg USE OF CAR-MODIFIED T LYMPHOCYTES FOR FLT3 AND FLT3 INHIBITORS FOR TREATING ACUTE MYELOID LEUKEMIA
CA3080197C (en) 2017-10-27 2023-12-19 Plexxikon Inc. Formulations of a compound modulating kinases
DK3755703T3 (da) 2018-02-20 2022-06-27 Incyte Corp N-(phenyl)-2-(phenyl)pyrimidin-4-carboxamidderivater og relaterede forbindelser som hpk1-inhibitorer til behandling af kræft
PE20210642A1 (es) 2018-07-13 2021-03-23 Gilead Sciences Inc Inhibidores de pd-1/pd-l1
KR101954370B1 (ko) * 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
KR102297587B1 (ko) 2018-08-07 2021-09-06 재단법인 대구경북첨단의료산업진흥재단 치환된 n-헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
CN113166110B (zh) 2018-12-12 2023-08-11 暨南大学 2-氨基嘧啶类化合物及其应用
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
KR20200102948A (ko) 2019-02-22 2020-09-01 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EP3928780A4 (en) 2019-02-22 2022-12-07 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A FLT3 INHIBITOR AND HYPOMETHYLATING AGENT FOR THE TREATMENT OF ACUTE MYELOIC LEUKEMIA
WO2020171649A1 (ko) 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EP3991733A4 (en) 2019-06-27 2023-07-05 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing flt3 inhibitor and chemotherapeutic agents
WO2021066443A1 (ko) 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2021159993A1 (en) 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibitors of interleukin-1 receptor associated kinase (irak) /fms-like receptor tyrosine kinase (flt3), pharmaceutical products thereof, and methods thereof
CN116583284A (zh) 2020-11-05 2023-08-11 韩美药品株式会社 用于治疗髓性白血病的包括flt3抑制剂的药物组合物
KR20230056331A (ko) 2021-10-20 2023-04-27 한미약품 주식회사 급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
AU2023372170A1 (en) 2022-11-04 2025-04-24 Hanmi Pharm. Co., Ltd. Novel crystalline form of a pyrimidine compound and pharmaceutical compositions comprising the same and methods of use thereof
CN120857931A (zh) 2022-12-10 2025-10-28 艾普托斯生物科学公司 用于治疗患有血液学恶性病的患者的方法
EP4719355A1 (en) 2023-05-31 2026-04-08 Hanmi Pharm. Co., Ltd. Solid dispersion of myeloid kinome inhibitors and pharmaceutical composition comprising the same

Also Published As

Publication number Publication date
CL2021002217A1 (es) 2022-04-29
JP2022521380A (ja) 2022-04-07
BR112021016522A2 (pt) 2021-10-26
JP7577672B2 (ja) 2024-11-05
WO2020171646A1 (ko) 2020-08-27
US20220110913A1 (en) 2022-04-14
US12433867B2 (en) 2025-10-07
PH12021551985A1 (en) 2022-08-22
PE20212153A1 (es) 2021-11-09

Similar Documents

Publication Publication Date Title
PH12021551985A1 (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
MX2021015724A (es) Composición farmacéutica para el tratamiento de la leucemia mieloide aguda, que contiene inhibidores de flt3 y agentes quimioterapéuticos.
MX2020011868A (es) Inhibidores de los receptores erbb.
MX2020007947A (es) Inhibidores de erbb/btk.
JOP20220130A1 (ar) مجموعات تترا هيدروفيوران بها استبدال في صورة عوامل تعديل لقنوات الصوديوم
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
MX385265B (es) Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas
MY208662A (en) Modulators of methyl modifying enzymes, compositions and uses thereof
MX2019013954A (es) Inhibidores covalentes de kras.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
EA202193015A1 (ru) Ингибиторы cdk
ZA202400988B (en) Aak1 inhibitor and use thereof
MX2024014861A (es) Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo
CO2023013050A2 (es) Composiciones de psilocibina, métodos para prepararlas y métodos de uso de estas
GEP20247627B (en) Macrocyclic compounds as sting agonists and methods and uses thereof
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
EA202191984A1 (ru) Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
MX2021007247A (es) Derivados de rapamicina.
MX2025003515A (es) Moduladores de akt1
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
MX2025005474A (es) Farmaco farmaceutico que contiene derivado de heterocicliden acetamida
MX2020010618A (es) Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a.
ZA202307855B (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
PH12020551772A1 (en) Oxo-substituted compound